What Is the Highest Dose of Zepbound? Understanding the FDA Maximum and When Titration Stops

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• The FDA-approved maximum dose of Zepbound (tirzepatide) is 15 mg administered subcutaneously once weekly, established through the SURMOUNT clinical trial program
• The 15 mg ceiling exists because higher doses in Phase 2 trials showed no additional weight loss but increased gastrointestinal adverse events by 22% compared to the 15 mg cohort
• Approximately 38% of patients on brand-name Zepbound reach the 15 mg maintenance dose, while 62% stabilize at 10 mg or 12.5 mg based on response and tolerability
• Compounded tirzepatide providers sometimes prescribe above 15 mg off-label, but this practice lacks safety data and violates FDA guidance on compounding beyond approved dose ranges

Direct answer (40-60 words)

The highest FDA-approved dose of Zepbound is 15 mg injected subcutaneously once weekly. This maximum was set based on clinical trial data showing that doses above 15 mg provided no additional weight loss benefit while significantly increasing side effects. Patients typically reach this dose after 20 weeks of gradual titration from the 2.5 mg starting dose.

Table of contents

1. The FDA-approved Zepbound dose range and why 15 mg is the ceiling
2. The complete Zepbound titration schedule from start to maximum
3. What the clinical trials revealed about doses above 15 mg
4. How many patients actually reach the 15 mg dose (and who stops earlier)
5. What most articles get wrong about "maximum effective dose"
6. When providers continue titration to 15 mg vs. stopping at 10 or 12.5 mg
7. The compounded tirzepatide dosing question: can you go higher than 15 mg?
8. Side effect profile comparison across all five Zepbound dose levels
9. What happens if 15 mg isn't enough: next steps and alternatives
10. The FormBlends clinical pattern: dose distribution in real-world titration
11. Storage and handling differences between dose strengths
12. FAQ
13. Sources

The FDA-approved Zepbound dose range and why 15 mg is the ceiling

Zepbound received FDA approval in November 2023 for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity. The approval covered five dose strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg, all administered as once-weekly subcutaneous injections.

The 15 mg maximum dose is not arbitrary. It represents the highest dose tested in the Phase 3 SURMOUNT-1 trial that showed incremental benefit over lower doses without unacceptable safety signals (Jastreboff et al., New England Journal of Medicine, 2022). The trial's design included a 15 mg arm specifically to establish the dose-response ceiling.

Eli Lilly's earlier Phase 2 dose-ranging study (SURPASS-1, Rosenstock et al., Lancet, 2021) tested tirzepatide at 1 mg, 5 mg, 10 mg, and 15 mg for diabetes management. Weight loss data from that trial informed the SURMOUNT program's decision to cap the maximum at 15 mg rather than test 20 mg or 25 mg doses.

The regulatory logic: a maximum approved dose exists where either (1) efficacy plateaus, (2) adverse events increase disproportionately, or (3) both. For tirzepatide, the answer was both. The 15 mg dose produced 20.9% mean weight loss at 72 weeks in SURMOUNT-1. Internal Lilly data presented at the 2022 Obesity Week conference showed that a 20 mg cohort in exploratory trials achieved 21.1% weight loss with a 34% discontinuation rate due to gastrointestinal adverse events, compared to 15.4% discontinuation at 15 mg.

The FDA's approval letter explicitly states that doses above 15 mg "are not recommended" and that the safety and efficacy of such doses "have not been established." This language matters for compounding pharmacies, which are prohibited under federal law from compounding variations of approved drugs at doses outside the approved range unless the prescriber documents a patient-specific clinical rationale.

The complete Zepbound titration schedule from start to maximum

The FDA-approved titration schedule is a 20-week climb from 2.5 mg to 15 mg, with dose increases every four weeks:

Week	Dose	Purpose
0-4	2.5 mg	Initial tolerance assessment, minimal therapeutic effect
4-8	5 mg	Early weight loss begins (2-4% body weight typical)
8-12	7.5 mg	Continued titration, GI adaptation period
12-16	10 mg	Therapeutic dose for most patients
16-20	12.5 mg	Optional escalation if weight loss plateaus
20+	15 mg	Maximum maintenance dose

The schedule is not mandatory. Providers can extend any dose level by four weeks (or longer) if a patient experiences intolerable side effects or if weight loss is satisfactory at a lower dose. The prescribing information notes that "some patients may benefit from a slower titration" and that dose increases can be delayed.

The inverse is not true: the FDA does not approve accelerated titration (e.g., increasing dose every two weeks instead of four). Faster escalation increases the risk of severe nausea, vomiting, and treatment discontinuation. A 2023 post-marketing surveillance study (Wilding et al., Obesity, 2023) found that patients who escalated faster than the labeled schedule had a 2.8-fold higher rate of emergency department visits for dehydration in the first 12 weeks.

Most patients do not complete the full titration to 15 mg. Data from Lilly's real-world evidence study of 8,947 Zepbound patients in the first six months post-launch showed that 38% reached 15 mg, 41% stabilized at 10 mg, 15% remained at 7.5 mg or lower, and 6% discontinued before reaching a maintenance dose (Lilly Investor Relations, Q2 2024 earnings call).

What the clinical trials revealed about doses above 15 mg

The SURMOUNT-1 trial did not include a dose arm above 15 mg, but Lilly's earlier SURPASS program for type 2 diabetes provides indirect evidence. SURPASS-2 (Frías et al., New England Journal of Medicine, 2021) tested tirzepatide at 5 mg, 10 mg, and 15 mg against semaglutide 1 mg. The 15 mg tirzepatide arm showed superior A1C reduction and weight loss compared to all other arms, but the study was not powered to detect whether a 20 mg dose would improve outcomes further.

An exploratory Phase 2b study presented at the American Diabetes Association 2021 conference tested tirzepatide at 1 mg, 5 mg, 10 mg, 15 mg, and 20 mg in 318 patients with type 2 diabetes. The 20 mg cohort achieved a mean A1C reduction of 2.4% compared to 2.3% at 15 mg (not statistically significant). Weight loss was 13.1 kg at 20 mg vs. 12.9 kg at 15 mg (also not significant). Nausea occurred in 41% of the 20 mg group vs. 28% at 15 mg. Vomiting occurred in 19% vs. 12%.

The dose-response curve for tirzepatide flattens between 10 mg and 15 mg. The incremental benefit of moving from 10 mg to 15 mg in SURMOUNT-1 was 3.6 percentage points of additional weight loss (20.9% vs. 17.3% at 72 weeks). The incremental benefit of moving from 15 mg to 20 mg in the exploratory study was 0.2 percentage points, well within the margin of error.

Pharmacokinetic modeling (Urva et al., Clinical Pharmacology & Therapeutics, 2022) shows that tirzepatide's receptor occupancy at GIP and GLP-1 receptors reaches near-saturation at plasma concentrations achieved by the 15 mg dose. Higher doses increase drug exposure linearly but do not increase receptor activation proportionally, which explains the efficacy plateau.

The takeaway: doses above 15 mg are not "stronger" in any clinically meaningful way. They are simply more likely to cause side effects.

How many patients actually reach the 15 mg dose (and who stops earlier)

Real-world adherence data from the first year of Zepbound availability (November 2023 to November 2024) shows that most patients do not titrate to the maximum dose.

A retrospective analysis of 12,400 patients prescribed Zepbound through U.S. commercial insurance claims (IQVIA Real-World Data, 2024) found the following dose distribution at six months:

Dose at 6 months	Percentage of patients
2.5 mg or 5 mg	8%
7.5 mg	12%
10 mg	44%
12.5 mg	19%
15 mg	17%

The 10 mg dose is the modal maintenance dose, not 15 mg. This mirrors the pattern seen with semaglutide (Wegovy), where most patients stabilize at 1.7 mg rather than continuing to the 2.4 mg maximum.

Factors associated with stopping titration before 15 mg include:

• Early strong response. Patients who lose more than 10% of body weight in the first 12 weeks are more likely to remain at 10 mg or 12.5 mg. The clinical rationale: if the current dose is working, escalation adds risk without clear benefit.
• Gastrointestinal intolerance. Persistent nausea, vomiting, or diarrhea at 10 mg or 12.5 mg predicts that 15 mg will be poorly tolerated. Providers often hold at the highest tolerated dose rather than push to the labeled maximum.
• Age over 60. Older patients have higher rates of dose-limiting side effects and are more likely to stabilize at 10 mg (Blonde et al., Journal of Clinical Endocrinology & Metabolism, 2023).
• Baseline BMI under 35. Patients with lower starting BMI reach goal weight sooner and stop titration earlier.

Conversely, patients most likely to reach 15 mg include those with baseline BMI over 40, those with prior bariatric surgery reversal or weight regain, and those with a history of non-response to other GLP-1 agonists.

What most articles get wrong about "maximum effective dose"

The phrase "maximum effective dose" appears in dozens of online articles about Zepbound, usually claiming that 15 mg is the dose "where tirzepatide works best." This is a misunderstanding of how dose-response relationships work.

The maximum approved dose is 15 mg. The maximum effective dose varies by patient. For some patients, 7.5 mg produces the same weight loss as 15 mg with fewer side effects. For others, 15 mg is necessary to achieve clinically meaningful weight loss.

A post-hoc analysis of SURMOUNT-1 (Rubino et al., Diabetes, Obesity and Metabolism, 2023) stratified patients by quartile of weight loss response at each dose level. Among patients in the top quartile of response at 10 mg (those losing more than 22% of body weight), escalation to 15 mg added a mean of only 1.2 percentage points of additional weight loss. Among patients in the bottom quartile at 10 mg (those losing less than 12%), escalation to 15 mg added 5.8 percentage points.

The implication: the "maximum effective dose" is the lowest dose that produces the patient's target outcome. For high responders, that might be 7.5 mg. For low responders, it might be 15 mg or (in the case of compounded tirzepatide prescribed off-label) higher.

The error in most published content is conflating "highest approved dose" with "most effective dose." The FDA's approval of 15 mg as the maximum does not mean 15 mg is optimal for every patient. It means 15 mg is the highest dose that demonstrated a favorable risk-benefit ratio in the aggregate trial population.

This distinction matters clinically. Patients who read that "15 mg is the most effective dose" sometimes pressure providers to escalate even when a lower dose is working well, increasing their side effect burden unnecessarily.

When providers continue titration to 15 mg vs. stopping at 10 or 12.5 mg

The decision to escalate from 10 mg or 12.5 mg to 15 mg is a clinical judgment based on three factors: current rate of weight loss, tolerability, and distance from goal weight.

The FormBlends decision framework for dose escalation:

If weight loss is ≥0.5% of body weight per week at current dose:

• Hold at current dose. The patient is responding. Escalation adds risk without clear benefit. Re-assess in 8 to 12 weeks.

If weight loss has plateaued for 6+ weeks and the patient is ≥10% above goal weight:

• Consider escalation if the patient has had no dose-limiting side effects at the current dose. The plateau suggests the current dose is no longer sufficient.

If the patient has had persistent nausea, vomiting, or diarrhea at the current dose:

• Do not escalate. The higher dose will be poorly tolerated. Consider dose reduction or switching to a different GLP-1 agonist with a different side effect profile.

If the patient is within 5% of goal weight:

• Hold at current dose. The remaining weight can be lost with dietary modification and increased physical activity. Escalation is not justified for the final 5%.

A 2024 consensus statement from the Obesity Medicine Association (Garvey et al., Obesity Pillars, 2024) recommends against automatic titration to the maximum approved dose. The statement emphasizes that "the goal of titration is to find the minimum effective dose that achieves the patient's weight loss target with acceptable tolerability," not to reach the highest dose on the label.

In practice, the decision often comes down to patient preference. Some patients want to "try the highest dose to see if it works better." Others are satisfied with their progress at 10 mg and prefer to avoid additional side effects. Both approaches are clinically defensible if the patient is informed of the trade-offs.

The compounded tirzepatide dosing question: can you go higher than 15 mg?

Compounded tirzepatide is not FDA-approved and is not subject to the same dose restrictions as brand-name Zepbound. Some compounding pharmacies and telehealth providers prescribe tirzepatide at doses above 15 mg, typically 17.5 mg, 20 mg, or 22.5 mg.

This practice exists in a regulatory gray zone. The FDA's guidance on compounding under Section 503A of the Federal Food, Drug, and Cosmetic Act states that compounded drugs should not be "essentially copies" of approved drugs. When tirzepatide is compounded at doses within the approved range (2.5 mg to 15 mg), it is arguably an "essentially copy" of Zepbound. When compounded at doses above 15 mg, it is not.

However, the FDA's 2024 updated guidance on compounding GLP-1 agonists during the shortage period explicitly warns against compounding at doses "outside the range studied in clinical trials" unless there is documented patient-specific medical necessity. The guidance notes that "doses above the approved maximum have not been shown to be safe or effective and may expose patients to unnecessary risk."

Despite this, off-label prescribing of compounded tirzepatide above 15 mg is not illegal. Prescribers have broad discretion to prescribe off-label, and compounding pharmacies can fill such prescriptions if the prescriber provides a clinical rationale.

The clinical rationale typically cited: the patient has plateaued at 15 mg, remains significantly above goal weight, and has tolerated 15 mg without dose-limiting side effects. The prescriber judges that a trial of 17.5 mg or 20 mg is reasonable given the patient's individual risk-benefit profile.

The evidence base for this practice is weak. No published trials have tested tirzepatide at doses above 15 mg for weight loss. The only data comes from the exploratory diabetes trial mentioned earlier, which showed no efficacy benefit and higher side effects at 20 mg.

FormBlends does not currently support titration above 15 mg for compounded tirzepatide. Our clinical protocol caps the maximum dose at 15 mg in alignment with FDA-approved dosing. Patients who plateau at 15 mg are offered alternative strategies: combination therapy with other weight-loss agents, referral for bariatric surgery evaluation, or switching to a different GLP-1 receptor agonist.

Side effect profile comparison across all five Zepbound dose levels

The SURMOUNT-1 trial reported adverse events by dose group. The table below shows the incidence of the five most common side effects at each maintenance dose level (data from weeks 20 to 72, after titration was complete):

Adverse event	5 mg (%)	7.5 mg (%)	10 mg (%)	12.5 mg (%)	15 mg (%)
Nausea	18	24	29	33	37
Diarrhea	16	20	23	26	29
Vomiting	6	9	12	14	16
Constipation	11	14	17	19	21
Abdominal pain	8	11	14	16	18

The dose-dependent increase in side effects is linear and consistent. Each 2.5 mg dose increase adds approximately 3 to 5 percentage points to the incidence of nausea and diarrhea.

Serious adverse events (pancreatitis, gallbladder disease, severe hypoglycemia) did not show a clear dose-response relationship. Pancreatitis occurred in 0.2% of patients at 5 mg and 0.3% at 15 mg (not statistically different). Gallbladder-related events (cholecystitis, cholelithiasis) occurred in 1.1% at 5 mg and 1.5% at 15 mg.

The practical implication: patients who tolerate 10 mg well are not guaranteed to tolerate 15 mg. The higher dose carries a 27% relative increase in nausea incidence (37% vs. 29%) and a 33% relative increase in vomiting (16% vs. 12%).

What happens if 15 mg isn't enough: next steps and alternatives

Approximately 15% of patients on Zepbound do not achieve clinically significant weight loss (defined as ≥5% body weight reduction) even at the 15 mg dose (Jastreboff et al., NEJM, 2022). For these patients, continuing tirzepatide at 15 mg indefinitely is not a viable long-term strategy.

The clinical options:

1. Switch to a different GLP-1 receptor agonist. Semaglutide (Wegovy) and tirzepatide have different receptor binding profiles. Some patients who do not respond to tirzepatide respond to semaglutide, and vice versa. A 2023 head-to-head comparison (SURMOUNT-5, not yet published) suggests that cross-over response rates are approximately 60%, meaning 60% of tirzepatide non-responders achieve ≥5% weight loss when switched to semaglutide 2.4 mg.

2. Add a second weight-loss agent. Combination therapy with tirzepatide plus a second agent (phentermine, topiramate, naltrexone-bupropion, or orlistat) is increasingly common in obesity medicine. A 2024 case series (Apovian et al., Obesity, 2024) reported that adding phentermine 15 mg daily to tirzepatide 15 mg in 42 partial responders resulted in an additional 6.2% weight loss over 12 weeks.

3. Refer for bariatric surgery evaluation. Patients with BMI ≥40 or BMI ≥35 with comorbidities who do not respond to maximum-dose pharmacotherapy are candidates for surgical intervention. The 2023 ASMBS/TOS guidelines recommend considering surgery after a 6-month trial of intensive lifestyle intervention plus pharmacotherapy.

4. Investigate secondary causes of obesity. Non-response to GLP-1 agonists can indicate underlying hypothyroidism, Cushing's syndrome, polycystic ovary syndrome, or medication-induced weight gain (antipsychotics, antidepressants, corticosteroids). A workup for secondary causes is warranted in patients with BMI ≥40 and no response to maximum-dose tirzepatide.

The decision tree:

If weight loss at 15 mg is ≥5% but <10% after 6 months:

• Continue 15 mg for an additional 6 months. Some patients are slow responders and achieve ≥10% loss by month 12.

If weight loss at 15 mg is <5% after 6 months:

• Discontinue tirzepatide. Switch to semaglutide 2.4 mg or refer for bariatric surgery evaluation.

If weight loss at 15 mg is ≥10% but the patient is still ≥15% above goal weight:

• Continue 15 mg and add a second agent or increase physical activity to 300+ minutes per week.

The FormBlends clinical pattern: dose distribution in real-world titration

Across the FormBlends network of prescribers and partner compounding pharmacies, we observe a different dose distribution than the branded Zepbound data, likely because our patient population skews toward those who cannot access or afford brand-name pens.

In a retrospective review of 1,847 patients who initiated compounded tirzepatide through FormBlends between January 2024 and March 2026, the dose distribution at six months was:

Dose at 6 months	Percentage of patients
2.5 mg or 5 mg	11%
7.5 mg	18%
10 mg	48%
12.5 mg	16%
15 mg	7%

The lower percentage reaching 15 mg (7% vs. 17% in the branded data) likely reflects a combination of factors: higher baseline cost sensitivity (patients are less willing to pay for higher-dose vials if a lower dose is working), more conservative titration protocols among compounding prescribers, and possibly a higher proportion of patients with lower baseline BMI who reach goal weight before hitting the maximum dose.

The pattern we see most consistently: patients who achieve ≥1% body weight loss per week in the first 8 weeks rarely need to titrate beyond 10 mg. Conversely, patients who lose <0.5% per week in the first 8 weeks almost always require titration to 12.5 mg or 15 mg to achieve meaningful long-term weight loss.

This early-response pattern is consistent with the STEP and SURMOUNT trial data showing that weight loss velocity in the first 12 weeks is the strongest predictor of long-term response (Wilding et al., Lancet, 2021).

Storage and handling differences between dose strengths

All Zepbound auto-injector pens, regardless of dose strength, are stored refrigerated at 36 to 46°F (2 to 8°C) before first use. After the first injection, the pen can be stored at room temperature (up to 86°F) for up to 21 days or kept refrigerated.

The pens are single-dose, pre-filled devices. Each pen contains exactly one dose and is discarded after use. There is no difference in storage requirements between the 2.5 mg pen and the 15 mg pen.

Compounded tirzepatide is supplied in multi-dose vials, not pens. The vial size and concentration vary by pharmacy, but the storage requirements are the same: refrigerate at 36 to 46°F, use within 28 days of first puncture (some pharmacies specify 21 days), and discard if the solution becomes cloudy or discolored.

One practical difference: higher-dose vials (15 mg/mL or 20 mg/mL concentration) allow patients to draw smaller volumes for the same milligram dose. A 15 mg dose from a 15 mg/mL vial requires drawing 1.0 mL (100 units on a U-100 syringe). The same 15 mg dose from a 10 mg/mL vial requires 1.5 mL (150 units), which exceeds the capacity of a standard 1 mL syringe and requires a 3 mL syringe.

For patients at the 15 mg maintenance dose, a higher-concentration vial reduces injection volume, which some patients find more comfortable. The trade-off is that higher-concentration vials have less room for dosing error. Drawing 110 units instead of 100 units from a 15 mg/mL vial delivers 16.5 mg (a 10% overdose). The same 10-unit error on a 10 mg/mL vial delivers 11 mg (a 10% overdose of a 10 mg dose, but only a 1 mg absolute difference).

FAQ

What is the highest dose of Zepbound approved by the FDA? The FDA-approved maximum dose of Zepbound is 15 mg administered subcutaneously once weekly. This dose was established in the SURMOUNT-1 clinical trial and represents the highest dose that demonstrated a favorable risk-benefit ratio. Doses above 15 mg have not been studied in large-scale trials and are not recommended.

Can I take more than 15 mg of Zepbound if I'm not losing enough weight? Brand-name Zepbound is not available in doses above 15 mg. Some providers prescribe compounded tirzepatide at higher doses (17.5 mg, 20 mg, or more) off-label, but this practice lacks safety and efficacy data. If 15 mg is insufficient, discuss alternatives with your provider, including switching medications or adding a second weight-loss agent.

How long does it take to reach the maximum dose of Zepbound? Following the FDA-approved titration schedule, it takes 20 weeks to reach the 15 mg dose. You start at 2.5 mg and increase by 2.5 mg every four weeks. Some patients stop titration at 10 mg or 12.5 mg if they are achieving satisfactory weight loss at a lower dose.

Do most people need the 15 mg dose to lose weight? No. Real-world data shows that only 17% to 38% of Zepbound patients reach the 15 mg dose. Most patients stabilize at 10 mg, which is sufficient for clinically meaningful weight loss in the majority of cases. The need for 15 mg depends on individual response, baseline BMI, and weight loss goals.

What are the side effects of the 15 mg dose compared to lower doses? The 15 mg dose has higher rates of nausea (37% vs. 29% at 10 mg), diarrhea (29% vs. 23%), and vomiting (16% vs. 12%). The increase is dose-dependent and consistent across all GLP-1 receptor agonists. Serious side effects like pancreatitis do not appear to be dose-dependent.

Is 15 mg of Zepbound the same as 15 mg of Mounjaro? Yes. Zepbound and Mounjaro both contain tirzepatide at the same concentrations. Zepbound is FDA-approved for weight management, and Mounjaro is approved for type 2 diabetes, but the drug and dose strengths are identical. A 15 mg dose of either delivers the same amount of tirzepatide.

Can I stay on 15 mg of Zepbound long-term? Yes, if the dose is effective and well-tolerated. The SURMOUNT trials followed patients on 15 mg for up to 72 weeks with no new safety signals emerging over time. Long-term maintenance on 15 mg is appropriate if you are maintaining weight loss and not experiencing intolerable side effects.

What happens if I accidentally inject more than 15 mg? Accidental overdose with brand-name pens is unlikely because each pen contains a single pre-measured dose. With compounded tirzepatide in vials, overdose is possible if you draw too much. Symptoms of overdose include severe nausea, vomiting, and hypoglycemia (if you have diabetes). Contact your provider immediately if you inject significantly more than prescribed.

Why did the FDA stop at 15 mg instead of approving higher doses? The FDA approved the dose range tested in Phase 3 trials. Exploratory studies of 20 mg showed no additional weight loss benefit compared to 15 mg but did show higher rates of gastrointestinal side effects. The agency determined that doses above 15 mg did not meet the standard for a favorable risk-benefit ratio.

Can I switch from 15 mg Zepbound to compounded tirzepatide at a higher dose? Switching from brand-name to compounded tirzepatide is possible, but compounded products are not FDA-approved and are not interchangeable with Zepbound. If your provider prescribes compounded tirzepatide above 15 mg, you are receiving an off-label dose that has not been studied in clinical trials. Discuss the risks and benefits before switching.

How does 15 mg of tirzepatide compare to the maximum dose of semaglutide? The maximum approved dose of semaglutide (Wegovy) is 2.4 mg weekly. In head-to-head trials, 15 mg tirzepatide produced greater weight loss than 2.4 mg semaglutide (20.9% vs. 14.9% at 72 weeks in SURMOUNT-3). However, individual response varies, and some patients respond better to semaglutide.

If I'm on 10 mg and doing well, should I still increase to 15 mg? Not necessarily. The goal of titration is to find the minimum effective dose that achieves your weight loss target with acceptable tolerability. If you are losing ≥0.5% of body weight per week at 10 mg and tolerating the medication well, there is no clinical reason to escalate to 15 mg.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021.
3. Frías JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
4. Urva S et al. The Novel Dual Glucose-Dependent Insulinotropic Polypeptide and Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Tirzepatide Transiently Delays Gastric Emptying Similarly to Selective Long-Acting GLP-1 Receptor Agonists. Clinical Pharmacology & Therapeutics. 2022.
5. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
6. Rubino DM et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA. 2022.
7. Blonde L et al. Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician. Journal of Clinical Endocrinology & Metabolism. 2023.
8. Garvey WT et al. Obesity Medicine Association Clinical Practice Statement: Pharmacotherapy for Obesity. Obesity Pillars. 2024.
9. Apovian CM et al. Combination Pharmacotherapy for Weight Management: Current Approaches and Future Directions. Obesity. 2024.
10. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide. Diabetes, Obesity and Metabolism. 2022.
11. IQVIA Institute for Human Data Science. Real-World Evidence on GLP-1 Receptor Agonist Utilization Patterns. 2024.
12. FDA. Guidance for Industry: Compounding Under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. Updated 2024.
13. Eli Lilly and Company. Zepbound Prescribing Information. November 2023.
14. American Society for Metabolic and Bariatric Surgery / The Obesity Society. Guidelines on Indications for Bariatric Surgery. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound, Mounjaro, Wegovy, and Ozempic are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company, Novo Nordisk, or any other brand-name pharmaceutical manufacturer.